USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Trends in Communicable and Non-Communicable Diseases Drug Pipeline
30-Sep-2015
Global
Market Research
P8C1-01-00-00-00
LS00152-GL-MR_16993
Immunoglobulin therapies are life-saving medicines that have been in use for more than 60 years. They provide the patient with a variety of antibodies and are often used as a last line of defense in many severe inflammatory diseases. In some conditions, they are life-saving. However, immunoglobulin therapies are expensive. Despite this, global demand for immunoglobulin is growing and the market is expected to foresee increased competition. As of 2015, more than 40 immunoglobulin treatments have been approved, with another 28 in various stages of development. This research service provides an overview of the marketed products and those in the pipeline. The analysis divides these treatments by the communicable and non-communicable diseases that they treat. In addition, key products and companies are profiled.
Key Findings
Key Findings (continued)
Major Milestones
Major Milestones (continued)
Scope of the Study
Immunoglobulin Overview
Classification of Immunoglobulins
Classification of Immunoglobulins (continued)
Treatment Guidelines
Treatment Guidelines (continued)
Market Overview
Market Overview (continued)
Market Overview (continued)
Overview of Drugs
Overview of Drugs (continued)
Competitive Landscape—Communicable Diseases Treatments
Competitive Landscape—Non-Communicable Diseases Treatments
Communicable Diseases Product Overview
Marketed Product Analysis
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Pipeline Product Analysis
Pipeline Product Analysis (continued)
Non-Communicable Diseases Product Overview
Marketed Product Analysis
Marketed Product Analysis (continued)
Marketed Product Analysis (continued)
Pipeline Product Analysis
Pipeline Product Analysis (continued)
Hizentra—CSL Behring
Civacir—Biotest
Flebogamma 10%—Grifols
GAMUNEX-C—Grifols
Privigen—CSL Behring
VariZIG—Cangene
Hepabulin IV—SK Holdings
Zutectra—Biotest
HyperTET—Grifols
Baxter International Inc.
Biotest AG
China Biologics Products, Inc.
CSL Behring Limited
Grifols
Octapharma AG
Kedrion Biopharma
Estimated Key Product Launch Timeline
Approval Dates
Conclusions—Future of Immunoglobulin Market
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Aish Vivekanadan |
| WIP Number | P8C1-01-00-00-00 |
| Keyword 1 | Global Immunoglobulin |
| Keyword 2 | Pipeline Analysis of the Immunoglobulin |
| Keyword 3 | Immunoglobulin Products |
| Is Prebook | No |
A Product and Pipeline Analysis of the Global Immunoglobulin Market
$4,950.00
Special Price $3,712.50 save 25 %